:16 am Valeant Pharma beats by $0.12, reports revs in-line; raises Q4, FY15 cash EPS guidance (VRX) : Reports Q3 (Sep) earnings of $2.11 per share, excluding non-recurring items, $0.12 better than the Capital IQ Consensus Estimate of $1.99; revenues rose 33.4% year/year to $2.06 bln vs the $2.06 bln consensus.
